Growth potential Strong niche: Neurescue’s ground-breaking fluoroscopy-free aortic occlusion device targets non-shockable cardiac arrest, a large unmet need with historically low survival. This creates a clear value proposition for hospital systems and EMS providers seeking innovative ED/ICU solutions to improve survival rates.

Clinical impact Immediate blood flow boost to heart and brain within one minute of deployment positions the device as a pivotal bridge to recovery, potential integration with heart-lung machines and PCI workflows. Sales conversations can center on improved outcomes, faster intervention readiness, and potential codes/quality metric benefits.

Market entry Recently funded with Series A and a growing narrative in cardiovascular emergency tech, Neurescue is likely to accelerate clinical trials and hospital pilots. Target early-adopter hospitals with stroke/neurology and cardiology/catheterization labs, highlighting rapid adoption and patient throughput improvements.

Strategic partnerships Opportunity to align with trauma centers, EMS networks, and perioperative services that manage cardiac arrest pathways. Propose combined training programs, data sharing on outcomes, and integration with existing cath lab and OR protocols to streamline procurement and deployment.

Financial readiness With revenue under $1M and total funding of about $11M, there is room for phased pilots and volume-based pricing negotiations. Emphasize scalable adoption across regional hospital networks and potential grant support for innovative resuscitation technologies.